II. To evaluate treatment effects on disease activation/progression, as indicated by measures of cardiac, pulmonary, gastrointestinal and renal function, as well as skin thickness, overall functional assessment (SHAQ), use of concomitant disease-modifying antirheumatic drugs (DMARDs), and occurrence of myositis.